New drug AZD5492 enters human testing for lupus, arthritis, and muscle disease
NCT ID NCT06916806
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 33 times
Summary
This early-phase study tests a new drug called AZD5492 in 72 adults with lupus, myositis, or rheumatoid arthritis. The main goal is to check safety and how the body handles the drug. Participants receive one or two injections and are monitored for up to a year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGAnniston, Alabama, 36207, United States
-
Research Site
WITHDRAWNBirmingham, Alabama, 35233, United States
-
Research Site
NOT_YET_RECRUITINGLa Jolla, California, 92037, United States
-
Research Site
NOT_YET_RECRUITINGSacramento, California, 95817, United States
-
Research Site
RECRUITINGIowa City, Iowa, 52242, United States
-
Research Site
NOT_YET_RECRUITINGOmaha, Nebraska, 68198, United States
-
Research Site
NOT_YET_RECRUITINGChapel Hill, North Carolina, 27599, United States
-
Research Site
NOT_YET_RECRUITINGHamilton, Ontario, L8S 4K1, Canada
-
Research Site
RECRUITINGSherbrooke, Quebec, J1G 2E8, Canada
-
Research Site
RECRUITINGBeijing, 100730, China
-
Research Site
RECRUITINGShanghai, 200001, China
-
Research Site
RECRUITINGWuhan, 430022, China
-
Research Site
NOT_YET_RECRUITINGZhengzhou, 450052, China
-
Research Site
RECRUITINGBordeaux, 33000, France
-
Research Site
RECRUITINGMontpellier, 34295, France
-
Research Site
RECRUITINGNancy, 54035, France
-
Research Site
RECRUITINGParis, 75013, France
-
Research Site
RECRUITINGStrasbourg, 67098, France
-
Research Site
RECRUITINGToulouse, 31059, France
-
Research Site
RECRUITINGCologne, 50937, Germany
-
Research Site
RECRUITINGErlangen, 91054, Germany
-
Research Site
NOT_YET_RECRUITINGMagdeburg, 39120, Germany
-
Research Site
NOT_YET_RECRUITINGPok Fu Lam, 999077, Hong Kong
-
Research Site
RECRUITINGBunkyō City, 113-8655, Japan
-
Research Site
RECRUITINGKita-gun, 761-0793, Japan
-
Research Site
RECRUITINGKitakyushu-shi, 807-8555, Japan
-
Research Site
RECRUITINGKyoto, 606-8501, Japan
-
Research Site
RECRUITINGNagasaki, 852-8501, Japan
-
Research Site
RECRUITINGAmsterdam, 1105 AZ, Netherlands
-
Research Site
WITHDRAWNLeiden, 2333, Netherlands
-
Research Site
RECRUITINGMérida, 06800, Spain
-
Research Site
RECRUITINGSeville, 41010, Spain
-
Research Site
RECRUITINGValladolid, 47012, Spain
-
Research Site
RECRUITINGGlasgow, G31 2ER, United Kingdom
-
Research Site
RECRUITINGLondon, SE5 9RS, United Kingdom
-
Research Site
RECRUITINGLondon, WC1E 6JF, United Kingdom
-
Research Site
RECRUITINGSouthampton, SO16 6YD, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD5492
What this could lead to
If successful, this could lead to a new treatment option for autoimmune diseases like lupus, myositis, and rheumatoid arthritis.
What could go wrong
This is a very early phase 1 trial focused on safety, not effectiveness. The drug may not work or could have side effects. Results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.